We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.8B
AUM Growth
-$295M
Cap. Flow
-$688M
Cap. Flow %
-3.02%
Top 10 Hldgs %
81.57%
Holding
135
New
6
Increased
16
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$58.8M
2
LEGN icon
Legend Biotech
LEGN
+$52.6M
3
HRTX icon
Heron Therapeutics
HRTX
+$34M
4
JBIO
Jade Biosciences
JBIO
+$32.6M
5
APLS
Apellis Pharmaceuticals
APLS
+$30.9M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$611M
2
NVTA
Invitae Corporation
NVTA
+$179M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$33.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$32.4M
5
ALT icon
Altimmune
ALT
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
51
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$31.7M 0.14%
223,976
– –
NVAX icon
52
Novavax
NVAX
$1.21B
$30.5M 0.13%
143,756
– –
ALKS icon
53
Alkermes
ALKS
$8.1B
$30.1M 0.13%
1,228,170
– –
BCEL
54
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$30.1M 0.13%
3,532,760
– –
DSGN icon
55
Design Therapeutics
DSGN
$750M
$28.6M 0.13%
1,436,636
– –
OPT
56
DELISTED
Opthea Limited American Depositary Shares
OPT
$27.1M 0.12%
3,412,062
+103,357
+3% +$920K
ACHL
57
DELISTED
Achilles Therapeutics
ACHL
$25.4M 0.11%
2,591,366
– –
SYRE icon
58
Spyre Therapeutics
SYRE
$8.49B
$23.7M 0.1%
136,404
– –
PTGX icon
59
Protagonist Therapeutics
PTGX
$8.55B
$20.4M 0.09%
455,276
-980,916
-68% -$32.4M
CYT
60
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$17.4M 0.08%
+812,640
New +$15.2M
CRNX icon
61
Crinetics Pharmaceuticals
CRNX
$8.88B
$17.4M 0.08%
920,656
+304,136
+49% +$5.34M
OTIC
62
DELISTED
Otonomy, Inc.
OTIC
$16.1M 0.07%
7,222,474
+2,400
+0% +$5.54K
KDNY
63
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$15.3M 0.07%
1,080,393
+331,700
+44% +$5.31M
AUPH icon
64
Aurinia Pharmaceuticals
AUPH
$1.95B
$14.5M 0.06%
1,119,962
-290,102
-21% -$3.7M
ALBO
65
DELISTED
Albireo Pharma Inc
ALBO
$14.5M 0.06%
412,466
– –
XENE icon
66
Xenon Pharmaceuticals
XENE
$6.09B
$14M 0.06%
751,639
– –
MIRM icon
67
Mirum Pharmaceuticals
MIRM
$6.54B
$11.2M 0.05%
647,313
– –
ANAB icon
68
AnaptysBio
ANAB
$1.54B
$11.1M 0.05%
427,179
– –
EWTX icon
69
Edgewise Therapeutics
EWTX
$4.28B
$10.7M 0.05%
500,000
– –
ALT icon
70
Altimmune
ALT
$568M
$10.6M 0.05%
1,072,038
-1,686,480
-61% -$23.1M
CBAY
71
DELISTED
Cymabay Therapeutics
CBAY
$9.46M 0.04%
2,170,464
– –
GTH
72
DELISTED
Genetron Holdings Limited ADS
GTH
$9.17M 0.04%
151,769
– –
CNTA
73
DELISTED
Centessa Pharmaceuticals
CNTA
$8.88M 0.04%
+400,000
New +$9.4M
ISEE
74
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.87M 0.04%
1,406,037
– –
LONA
75
LeonaBio Inc
LONA
$65.3M
$8.26M 0.04%
80,637
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Baker Bros. Advisors held 135 positions worth $22.8B, down 1.3% from $23.1B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors withdrew a net $688M in Q2 2021, closing 15 positions and reducing 10 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $611M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Verve Therapeutics worth $85.3M.

  • Baker Bros. Advisors's largest Q2 2021 buy was Verve Therapeutics: 1,416,530 shares worth $85.3M.
  • Baker Bros. Advisors added most to Legend Biotech in Q2 2021, an estimated $52.6M increase.
  • Baker Bros. Advisors's biggest Q2 2021 reduction was Invitae Corporation, cutting an estimated $179M.
  • Baker Bros. Advisors fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $611M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $22.8B portfolio in Q2 2021.
  • Baker Bros. Advisors opened 6 new positions and closed 15 in Q2 2021.
  • Baker Bros. Advisors's portfolio value fell 1.3% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.